A. Gordon Smith, MD, FAAN
A. Gordon Smith, MD, FAAN, is Professor and Chair of the Department of Neurology at Virginia Commonwealth University. Prior to this role, he served as Vice Chair for Research, Chief of the Division of Neuromuscular Medicine and Director of the Jack H. Petajan EMG Laboratory at the University of Utah. Smith is a graduate of the University of Virginia and the Mayo Medical School. He completed his neurology residency and a neuromuscular fellowship at the University of Michigan.
Smith’s NIH funded research team focuses on peripheral neuropathy in diabetes and obesity. He has a particular interest in biomarker development and novel clinical trial design in peripheral neuropathy. He was principal investigator of the Utah Regional site in the NINDS-funded Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), and sits on the NeuroNEXT Executive Committee. Smith is PI of the Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (TopCSPN) trial being performed by NeuroNEXT. TopCSPN is the first large scale randomized trial of a treatment to alter the natural history of CSPN, which is one of the most common neurological disorders. He is also PI of the Activity for Diabetic Neuropathy (ADAPT) Trial. Smith has led or participated in numerous clinical trials in neuromuscular disorders including the Impaired Glucose Tolerance Neuropathy Study (IGTN) and the Utah Diabetic Neuropathy Study (UDNS).
Smith serves on the Board of Directors of the American Academy of Neurology and Board of Trustees of the American Brain Foundation